JP2011528551A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528551A5
JP2011528551A5 JP2011518935A JP2011518935A JP2011528551A5 JP 2011528551 A5 JP2011528551 A5 JP 2011528551A5 JP 2011518935 A JP2011518935 A JP 2011518935A JP 2011518935 A JP2011518935 A JP 2011518935A JP 2011528551 A5 JP2011528551 A5 JP 2011528551A5
Authority
JP
Japan
Prior art keywords
dab
antigen
seq
disease
polypeptide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011518935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528551A (ja
JP5675608B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/050985 external-priority patent/WO2010009391A1/en
Publication of JP2011528551A publication Critical patent/JP2011528551A/ja
Publication of JP2011528551A5 publication Critical patent/JP2011528551A5/ja
Application granted granted Critical
Publication of JP5675608B2 publication Critical patent/JP5675608B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011518935A 2008-07-18 2009-07-17 Ｃｄ２８結合のための一価組成物および使用方法 Expired - Fee Related JP5675608B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8207808P 2008-07-18 2008-07-18
US61/082,078 2008-07-18
US16212109P 2009-03-20 2009-03-20
US61/162,121 2009-03-20
PCT/US2009/050985 WO2010009391A1 (en) 2008-07-18 2009-07-17 Compositions monovalent for cd28 binding and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014261305A Division JP5876134B2 (ja) 2008-07-18 2014-12-24 Ｃｄ２８結合のための一価組成物および使用方法

Publications (3)

Publication Number Publication Date
JP2011528551A JP2011528551A (ja) 2011-11-24
JP2011528551A5 true JP2011528551A5 (https=) 2012-08-30
JP5675608B2 JP5675608B2 (ja) 2015-02-25

Family

ID=41226147

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011518935A Expired - Fee Related JP5675608B2 (ja) 2008-07-18 2009-07-17 Ｃｄ２８結合のための一価組成物および使用方法
JP2014261305A Expired - Fee Related JP5876134B2 (ja) 2008-07-18 2014-12-24 Ｃｄ２８結合のための一価組成物および使用方法
JP2016009024A Expired - Fee Related JP6058833B2 (ja) 2008-07-18 2016-01-20 Ｃｄ２８結合のための一価組成物および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014261305A Expired - Fee Related JP5876134B2 (ja) 2008-07-18 2014-12-24 Ｃｄ２８結合のための一価組成物および使用方法
JP2016009024A Expired - Fee Related JP6058833B2 (ja) 2008-07-18 2016-01-20 Ｃｄ２８結合のための一価組成物および使用方法

Country Status (29)

Country Link
US (6) US8168759B2 (https=)
EP (2) EP2321352B1 (https=)
JP (3) JP5675608B2 (https=)
KR (2) KR101791372B1 (https=)
CN (2) CN105936648B (https=)
AR (1) AR072571A1 (https=)
AU (1) AU2009270726B2 (https=)
CA (1) CA2731220C (https=)
CL (2) CL2011000117A1 (https=)
CO (1) CO6341641A2 (https=)
CY (1) CY1121796T1 (https=)
DK (2) DK2321352T3 (https=)
EA (1) EA024585B1 (https=)
ES (2) ES2562629T3 (https=)
HR (2) HRP20160329T1 (https=)
HU (2) HUE045249T2 (https=)
IL (2) IL210413A (https=)
LT (1) LT2700651T (https=)
ME (1) ME02396B (https=)
MX (1) MX2011000501A (https=)
NZ (1) NZ590343A (https=)
PE (2) PE20110385A1 (https=)
PL (2) PL2700651T3 (https=)
PT (2) PT2700651T (https=)
RS (2) RS54675B1 (https=)
SI (2) SI2700651T1 (https=)
SM (2) SMT201900367T1 (https=)
TW (2) TW201336510A (https=)
WO (1) WO2010009391A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
AR072571A1 (es) 2008-07-18 2010-09-08 Bristol Myers Squibb Co Composiciones monovalentes para union a cd28 y procedimientos de uso
SI2401373T1 (sl) * 2009-02-25 2014-02-28 Nextera As Signalni sekvenčno neodvisen pix prikaz faga
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
EP2361935A1 (en) * 2010-02-18 2011-08-31 TcL Pharma Anti-CD28 humanized antibodies
EP2536764B1 (en) 2010-02-18 2018-07-04 OSE Immunotherapeutics Anti-cd28 humanized antibodies
BR112012030311A2 (pt) * 2010-06-08 2017-01-24 Genentech Inc anticorpo
JP5768022B2 (ja) * 2012-03-19 2015-08-26 株式会社東芝 メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
BR112016014824A2 (pt) * 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
EA201691634A1 (ru) 2014-03-19 2016-11-30 Бристол-Маерс Сквибб Компани Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
EP3201231B1 (en) * 2014-09-30 2020-03-04 Bristol-Myers Squibb Company Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28
WO2017160975A1 (en) 2016-03-16 2017-09-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
AU2018250641B2 (en) 2017-04-11 2025-03-13 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
US12139534B2 (en) 2018-03-15 2024-11-12 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor CD28
BR112020020604A2 (pt) 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
AU2019288635A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
JP7332691B2 (ja) * 2018-07-08 2023-08-23 スペシフィカ インコーポレイティド 抗体の開発可能性が最大化された抗体ライブラリー
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
US12385913B2 (en) 2018-08-03 2025-08-12 Bristol-Myers Squibb Company Methods for detecting anti-drug antibodies
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020183473A1 (en) * 2019-03-14 2020-09-17 Biond Biologics Ltd. Small shedding blocking agents
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
ES2821599A1 (es) * 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
EP4069299A4 (en) * 2019-12-02 2024-06-12 Biond Biologics Ltd. Use of mmp inhibition
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN115380047A (zh) * 2020-01-29 2022-11-22 印希比股份有限公司 Cd28单结构域抗体及其多价和多特异性构建体
US12589163B2 (en) 2020-03-12 2026-03-31 Biond Biologics Ltd. Shedding blocking agents with increased stability
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
AU2021322183A1 (en) * 2020-08-04 2023-03-02 Exelixis, Inc. PD-L1 binding agents and uses thereof
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
JP2024532970A (ja) * 2021-09-06 2024-09-11 ビオンド バイオロジックス リミテッド Ｃｄ２８シェディング遮断剤
EP4519326A1 (en) * 2022-05-04 2025-03-12 Janux Therapeutics, Inc. Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
WO2023215498A2 (en) * 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
CA3267921A1 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. MULTISPECIFIC PROTEINS AND ASSOCIATED PROCESSES
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839295A (en) 1984-06-08 1989-06-13 Pierce Chemical Company Measurement of protein using bicinchoninic acid
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
ATE201983T1 (de) 1995-03-10 2001-06-15 Roche Diagnostics Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
CA2292415A1 (en) 1997-06-20 1998-12-30 Innogenetics N.V. B7-binding molecules for treating immune diseases
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AU766959B2 (en) 1998-04-20 2003-10-30 Genzyme Corporation Drug delivery of proteins from polymeric blends
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2372198A1 (en) 1999-05-14 2000-11-23 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
US20020006403A1 (en) * 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
ES2353273T3 (es) 2000-12-26 2011-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos anti-cd28.
US20080095774A1 (en) 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
CA2763913C (en) 2001-08-10 2014-10-28 Aberdeen University Antigen binding domains
US20050130124A1 (en) 2001-10-05 2005-06-16 Wiersma Erik J. Phagemid display system
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
CN100376599C (zh) * 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
CN101061140B (zh) * 2004-09-17 2015-07-01 多曼蒂斯有限公司 单价结合cd40l的组合物和应用方法
GB0614093D0 (en) 2006-07-14 2006-08-23 Bae Systems Plc Deployable antenna system
EP2102241A2 (en) * 2006-12-15 2009-09-23 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
AR072571A1 (es) * 2008-07-18 2010-09-08 Bristol Myers Squibb Co Composiciones monovalentes para union a cd28 y procedimientos de uso
CN102119172A (zh) 2008-08-21 2011-07-06 奥克塔法马股份有限公司 重组制备的人类因子viii和ix
EA201691634A1 (ru) * 2014-03-19 2016-11-30 Бристол-Маерс Сквибб Компани Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l
EP3201231B1 (en) * 2014-09-30 2020-03-04 Bristol-Myers Squibb Company Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28

Similar Documents

Publication Publication Date Title
JP2011528551A5 (https=)
Lykhopiy et al. IL-2 immunotherapy for targeting regulatory T cells in autoimmunity
ME02396B (me) Smješe monovalentne za vezivanje sa cd28 i metodi upotrebe
CA2507530C (en) Rapamycin and il-10 for the treatment of immune diseases
Zhou et al. Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease
US10800828B2 (en) Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
AU2014337367B2 (en) Peptidic chimeric antigen receptor T cell switches and uses thereof
Morris et al. Advances in interleukin 2 receptor targeted treatment
Kim et al. New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation
Choi et al. Current and emerging strategies for the prevention of graft-versus-host disease
AU2025237926A1 (en) Nanoparticle compositions for sustained therapy
JP2024071445A5 (https=)
Semerano et al. Novel immunotherapeutic avenues for rheumatoid arthritis
Liu et al. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease
Kebriaei et al. Treatment of graft-versus-host-disease with mesenchymal stromal cells
JP2010505830A5 (https=)
JP2018537962A5 (https=)
US20240166641A1 (en) Heterocycles and uses thereof
WO2016168766A1 (en) Optimized chimeric receptor t cell switches and uses thereof
JP2013508392A5 (https=)
CN108883180A (zh) Clec9a结合剂及其用途
WO2012125680A1 (en) Methods of treating vasculitis using an il-17 binding molecule
JP2015524413A5 (https=)
Yang et al. Therapeutic application of T regulatory cells in composite tissue allotransplantation
JP2020527044A5 (https=)